• Divya Pawar
• Pragati Kadam
• Reshma Ghadge
• Pooja Kadam
• Vivekkumar Redasani

A multifunctional autoimmune disease with an unclear cause, rheumatoid arthritis primarily affects the joints, though it can also appear extra-articularly. Good RA care necessitates a multidisciplinary approach due to its complexity, which is based on a pathophysiological process that is not fully understood. Recent improvements in diagnosis and treatment of RA have improved the clinical condition of patients by preventing systemic consequences and reducing disease activity. The development of disease-modifying anti-rheumatic medicines (DMARDs), which include standard synthetic, biologic, and targeted synthetic medications, has produced the most promising results. In addition, continuous medication development has produced molecules with enhanced safety and efficacy profiles; nonetheless, additional investigation is required until RA becomes a pathology that can be treated. Positive outcomes for RA patients need an early and precise diagnosis together with the best available personalized therapy.

RA (Rheumatoid arthritis), rheumatoid factor, Autoimmune Disease, Chronic inflammation, DMARDs(Disease modifying antirheumatic drugs), Immune response, Synoviocytes.

"Rheumatoid Arthritis: Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 6, page no.a52-a64, June-2024, Available :http://www.jetir.org/papers/JETIR2406008.pdf

"Rheumatoid Arthritis: Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 6, page no. ppa52-a64, June-2024, Available at : http://www.jetir.org/papers/JETIR2406008.pdf